INSYS Therapeutics Inc. (INSY)

8.15
NASDAQ : Health Technology
Prev Close 8.41
Day Low/High 8.03 / 8.48
52 Wk Low/High 4.10 / 14.00
Avg Volume 639.80K
Exchange NASDAQ
Shares Outstanding 73.81M
Market Cap 620.73M
EPS -3.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Seven U.S. Stocks Offering Cannabis Exposure

Seven U.S. Stocks Offering Cannabis Exposure

While cannabis remains illegal on a federal level, these seven names are making early inroads into the growing industry.

First Week Of INSY July 20th Options Trading

Investors in Insys Therapeutics Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

First Week Of November 16th Options Trading For Insys Therapeutics (INSY)

First Week Of November 16th Options Trading For Insys Therapeutics (INSY)

Investors in Insys Therapeutics Inc saw new options become available this week, for the November 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis subsidiary Sandoz Canada will work with cannabis producer Tilray to produce non-smokable medical cannabis products in Canada, becoming the first Big Pharma company to get into medical pot.

INSYS Therapeutics Reports Fourth Quarter And Full Year 2017 Results

INSYS Therapeutics Reports Fourth Quarter And Full Year 2017 Results

Foundation to become global leader in pharmaceutical cannabinoids and spray technology established in 2017 through new leadership and acceleration of product pipeline

Commit To Buy Insys Therapeutics At $5, Earn 26.7% Annualized Using Options

Commit To Buy Insys Therapeutics At $5, Earn 26.7% Annualized Using Options

Investors eyeing a purchase of Insys Therapeutics Inc stock, but tentative about paying the going market price of $7.57/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $5 strike, which has a bid at the time of this writing of 60 cents.

INSYS Therapeutics Initiates Phase 3 Clinical Trial Of Cannabidiol (CBD) Oral Solution For Treatment Of Infantile Spasms

INSYS Therapeutics Initiates Phase 3 Clinical Trial Of Cannabidiol (CBD) Oral Solution For Treatment Of Infantile Spasms

Pivotal study aims to evaluate safety and efficacy of company's novel CBD product candidate in rare type of pediatric epilepsy

First Week of April 20th Options Trading For Insys Therapeutics (INSY)

First Week of April 20th Options Trading For Insys Therapeutics (INSY)

Investors in Insys Therapeutics Inc saw new options begin trading this week, for the April 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new April 20th contracts and identified one put and one call contract of particular interest.

The Hottest Investing Plays in the Booming Weed Industry for 2018

The Hottest Investing Plays in the Booming Weed Industry for 2018

Marijuana stocks are still in their infancy, meaning there's a whole host of weed-adjacent stock moves waiting to be made. Here are the best bets.

Opioid Litigants Get Boost From Senate Report

Opioid Litigants Get Boost From Senate Report

A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period.

First Week of March 16th Options Trading For Insys Therapeutics (INSY)

First Week of March 16th Options Trading For Insys Therapeutics (INSY)

Investors in Insys Therapeutics Inc saw new options become available this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new March 16th contracts and identified one put and one call contract of particular interest.

INSY Crosses Above Average Analyst Target

INSY Crosses Above Average Analyst Target

In recent trading, shares of Insys Therapeutics Inc have crossed above the average analyst 12-month target price of $12.75, changing hands for $13.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

Consumers in California eagerly await the end to it prohibition on the recreational use of cannabis.

First Week of August 2018 Options Trading For Insys Therapeutics (INSY)

First Week of August 2018 Options Trading For Insys Therapeutics (INSY)

Investors in Insys Therapeutics Inc saw new options become available this week, for the August 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

INSYS Therapeutics Initiates Phase 2 Clinical Trial Of Cannabidiol (CBD) Oral Solution For Treatment Of Refractory Childhood Absence Epilepsy In Pediatric Patients

INSYS Therapeutics Initiates Phase 2 Clinical Trial Of Cannabidiol (CBD) Oral Solution For Treatment Of Refractory Childhood Absence Epilepsy In Pediatric Patients

Proof-of-concept study aims to assess efficacy, safety, tolerability and pharmacokinetics of company's novel CBD product candidate

INSYS Therapeutics Starts Proof-of-Concept Study Of Epinephrine Nasal Spray For Anaphylaxis

INSYS Therapeutics Starts Proof-of-Concept Study Of Epinephrine Nasal Spray For Anaphylaxis

Using standard intramuscular injection as comparator, company's Phase 1 clinical trial enrolls first patient

TheStreet Quant Rating: E+ (Sell)